

R H I N O M E D

ASX ANNOUNCEMENT

Not for release to U.S. wire services or distribution in the United States

Lifting of Trading Halt

11 April 2022: Melbourne, Australia.

Rhinomed Limited (ASX: RNO) (**Rhinomed**) is pleased to announce that, further to its ASX announcement dated 8 April 2022 regarding the successful completion of the institutional component of the partially underwritten accelerated non-renounceable entitlement offer (**Institutional Entitlement Offer**), the current Trading Halt will be lifted before market open today.

The timetable below for the Rhinomed's current capital raising is set out below. This timetable is indicative only and subject to change. Rhinomed reserves the right to alter the dates at its discretion and without prior notice, subject to the ASX Listing Rules and the *Corporations Act 2001* (Cth).

The quotation of New Shares is subject to confirmation from the ASX.

All times below are based on Melbourne time.

Action	Date
Request trading halt before market open	Before market open, Thursday, 7 April 2022
Announcement Entitlement Offer; Release of Investor Presentation, Appendix 3B and 708AA Cleansing Notice	Before 12 noon AEDT on Thursday, 7 April 2022
Conduct Institutional offer before the resumption of trading following the trading halt	Thursday, 7 April 2022 and Friday, 8 April 2022
Announcement of Institutional Entitlement Offer results	Friday, 8 April 2022
Trading halt lifted	Market open, Monday, 11 April 2022
Record Date for eligibility in the Entitlement Offer	7.00pm on Monday, 11 April 2022
Retail Entitlement Offer opens and Retail Offer Booklet despatched	Wednesday, 13 April 2022
Settlement of the New Shares issued under the Institutional Entitlement Offer	Before 12 noon AEDT on Thursday, 14 April 2022
Allotment and normal trading on ASX of New Shares issued under the Institutional Entitlement Offer	Tuesday, 19 April 2022
Retail Entitlement Offer closes	5.00pm on Friday, 29 April 2022
Announce results of Retail Entitlement Offer; Settlement of the New Shares issued under the Retail Entitlement Offer	Wednesday, 4 May 2022

R H I N O M E D

Action	Date
Allotment of New Shares issued under the Retail Entitlement Offer	Friday, 6 May 2022
Normal trading on ASX of New Shares issued under the Retail Entitlement Offer	Monday, 9 May 2022

This report has been authorised for release to the market by the Board.

All dollar amounts are in Australian dollars unless otherwise indicated.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.